Loading...

We've got a brand new version of Simply Wall St! Try it out

Synmosa Biopharma

GTSM:4114
Snowflake Description

Overvalued with poor track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4114
GTSM
NT$5B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
4114 Share Price and Events
7 Day Returns
-0.4%
GTSM:4114
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
2.9%
GTSM:4114
16%
TW Pharmaceuticals
17.7%
TW Market
4114 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Synmosa Biopharma (4114) -0.4% -1.7% -5.2% 2.9% 13.8% 4.9%
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 4114 underperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 4114 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4114
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Synmosa Biopharma's competitors could be found in our database.

4114 Value

 Is Synmosa Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Synmosa Biopharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Synmosa Biopharma.

GTSM:4114 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in TWD NT$ .175600
Payout Ratio Company Filings (2019-09-30) 847.5%
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4114
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (56.03%))
0.794
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for GTSM:4114 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Synmosa Biopharma is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

GTSM:4114 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= NT$0.18 / (7.5% - 2.73%)
NT$1.96
GTSM:4114 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$1.96
Current discount Discount to share price of NT$23.80
= -1 x (NT$23.80 - NT$1.96) / NT$1.96
-1114%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Synmosa Biopharma is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Synmosa Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Synmosa Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4114 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$0.18
GTSM:4114 Share Price ** GTSM (2019-11-18) in TWD NT$23.8
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Synmosa Biopharma.

GTSM:4114 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4114 Share Price ÷ EPS (both in TWD)

= 23.8 ÷ 0.18

134.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synmosa Biopharma is overvalued based on earnings compared to the TW Pharmaceuticals industry average.
  • Synmosa Biopharma is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Synmosa Biopharma's expected growth come at a high price?
Raw Data
GTSM:4114 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 134.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Synmosa Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Synmosa Biopharma's assets?
Raw Data
GTSM:4114 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$14.16
GTSM:4114 Share Price * GTSM (2019-11-18) in TWD NT$23.8
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:4114 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4114 Share Price ÷ Book Value per Share (both in TWD)

= 23.8 ÷ 14.16

1.68x

* Primary Listing of Synmosa Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synmosa Biopharma is good value based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Synmosa Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Synmosa Biopharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4114 Future Performance

 How is Synmosa Biopharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Synmosa Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Synmosa Biopharma expected to grow at an attractive rate?
  • Unable to compare Synmosa Biopharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Synmosa Biopharma's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Synmosa Biopharma's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4114 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4114 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4114 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
GTSM:4114 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 2,579 -54 40
2019-06-30 2,486 -11 61
2019-03-31 2,384 128 73
2018-12-31 2,363 16 431
2018-09-30 2,249 -106 432
2018-06-30 2,119 57 409
2018-03-31 2,017 9 379
2017-12-31 1,861 -5 5
2017-09-30 1,795 76 -34
2017-06-30 1,772 20 -38
2017-03-31 1,821 144 -6
2016-12-31 1,865 236 165

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Synmosa Biopharma is high growth as no earnings estimate data is available.
  • Unable to determine if Synmosa Biopharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4114 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Synmosa Biopharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4114 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
GTSM:4114 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 0.18
2019-06-30 0.28
2019-03-31 0.33
2018-12-31 1.94
2018-09-30 1.94
2018-06-30 1.83
2018-03-31 1.69
2017-12-31 0.02
2017-09-30 -0.15
2017-06-30 -0.17
2017-03-31 -0.03
2016-12-31 0.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Synmosa Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Synmosa Biopharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Synmosa Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Synmosa Biopharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4114 Past Performance

  How has Synmosa Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Synmosa Biopharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Synmosa Biopharma's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Synmosa Biopharma's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Synmosa Biopharma's 1-year earnings growth is negative, it can't be compared to the TW Pharmaceuticals industry average.
Earnings and Revenue History
Synmosa Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Synmosa Biopharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4114 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 2,579.10 40.49 796.15 207.34
2019-06-30 2,485.77 61.40 802.55 198.40
2019-03-31 2,383.72 73.33 807.10 190.89
2018-12-31 2,363.20 430.90 826.08 183.74
2018-09-30 2,248.79 432.26 788.58 192.54
2018-06-30 2,118.80 408.69 757.58 216.24
2018-03-31 2,016.91 378.55 702.71 201.54
2017-12-31 1,860.94 4.69 645.61 187.74
2017-09-30 1,795.28 -34.49 651.68 183.14
2017-06-30 1,772.24 -37.90 645.00 141.85
2017-03-31 1,821.09 -5.79 672.94 149.23
2016-12-31 1,865.25 165.32 711.17 146.41
2016-09-30 1,893.97 172.67 730.69 134.38
2016-06-30 1,926.36 179.75 734.04 137.23
2016-03-31 1,855.84 180.25 710.31 132.24
2015-12-31 1,776.41 31.54 671.13 130.83
2015-09-30 1,705.93 57.57 649.36 137.70
2015-06-30 1,644.30 74.72 634.54 140.02
2015-03-31 1,562.50 96.72 624.31 149.58
2014-12-31 1,476.01 110.27 602.09 139.62
2014-09-30 1,423.17 122.16 567.73 125.49
2014-06-30 1,329.33 106.53 528.32 112.92
2014-03-31 1,274.80 90.93 496.27 95.87
2013-12-31 1,249.24 62.93 474.26 94.01
2013-09-30 1,206.79 49.67 455.81 88.30
2013-06-30 1,177.34 52.81 445.40 86.51
2013-03-31 1,119.61 4.47 423.57 87.37
2012-12-31 1,065.02 98.28 410.45 96.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Synmosa Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Synmosa Biopharma used its assets less efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if Synmosa Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Synmosa Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Synmosa Biopharma has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4114 Health

 How is Synmosa Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Synmosa Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Synmosa Biopharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Synmosa Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Synmosa Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Synmosa Biopharma Company Filings, last reported 1 month ago.

GTSM:4114 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 4,463.49 2,906.91 568.19
2019-06-30 4,438.59 3,270.68 575.12
2019-03-31 4,516.68 2,874.68 352.85
2018-12-31 4,485.24 2,411.68 447.13
2018-09-30 4,724.57 2,446.02 284.18
2018-06-30 4,659.01 2,326.18 265.72
2018-03-31 4,720.51 2,585.65 605.43
2017-12-31 3,965.40 2,533.19 401.62
2017-09-30 4,149.15 2,310.37 579.23
2017-06-30 4,229.79 2,187.52 490.46
2017-03-31 4,343.05 1,926.65 524.28
2016-12-31 4,352.75 1,758.89 633.69
2016-09-30 4,500.00 1,647.30 875.41
2016-06-30 3,980.85 2,189.50 896.58
2016-03-31 3,770.56 2,111.72 628.56
2015-12-31 3,014.19 1,196.22 251.88
2015-09-30 3,065.32 1,111.17 215.52
2015-06-30 3,143.58 926.75 198.43
2015-03-31 3,191.04 822.30 302.33
2014-12-31 3,159.75 803.26 399.18
2014-09-30 3,182.86 796.01 468.08
2014-06-30 2,912.82 853.70 1,389.80
2014-03-31 2,700.18 894.08 1,368.13
2013-12-31 2,194.07 804.84 840.22
2013-09-30 1,403.77 808.18 407.72
2013-06-30 1,304.64 699.55 245.69
2013-03-31 1,265.54 647.29 253.54
2012-12-31 1,149.96 689.12 296.37
  • Synmosa Biopharma's level of debt (65.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (25% vs 65.1% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Synmosa Biopharma's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Synmosa Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Synmosa Biopharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4114 Dividends

 What is Synmosa Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.74%
Current annual income from Synmosa Biopharma dividends.
If you bought NT$2,000 of Synmosa Biopharma shares you are expected to receive NT$15 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Synmosa Biopharma's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.57%).
  • Synmosa Biopharma's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4114 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4114 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
GTSM:4114 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-28 0.176 0.689
2017-11-14 0.143 0.598
2017-03-31 0.143 0.664
2017-03-30 0.143 0.599
2016-05-10 0.131 0.588
2016-03-24 0.131 0.578
2015-05-14 0.121 0.566
2015-03-30 0.121 0.497
2014-05-12 0.113 0.434
2013-11-14 0.106 0.475
2013-08-14 0.106 0.457
2013-05-15 0.106 0.539
2013-03-29 0.106 0.540
2012-10-30 0.000 0.000
2011-08-30 0.048 0.334
2011-04-29 0.048 0.302
2010-10-29 0.000 0.000
2010-10-15 0.000 0.000
2010-08-30 0.000 0.000
2010-07-15 0.000 0.000
2010-04-30 0.000 0.000
2010-04-15 0.000 0.000
2009-11-02 0.000 0.000
2009-10-15 0.000 0.000
2009-08-31 0.000 0.000
2009-07-15 0.000 0.000
2009-04-15 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synmosa Biopharma is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are stable.
  • Synmosa Biopharma is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Synmosa Biopharma's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Synmosa Biopharma's dividends as it is not paying a notable one for Taiwan, Province of China.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Synmosa Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Synmosa Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Synmosa Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4114 Management

 What is the CEO of Synmosa Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Lin
CEO Bio

Mr. Peter Lin serves as Chairman and President of Synmosa Biopharma Corp. Mr. Lin is the key founder of Synmosa Group. By learning and observing from his favorite game-Go, Mr. Lin always thinks logically, strategically and thoroughly for every movement he takes. Mr. Lin is dedicated to improving the quality of human life by establishing a pharmaceutical research center in Taiwan and developing innovative new medicines. Mr. Lin graduated from Taipei Medical University with pharmacist degree.

CEO Compensation
  • Insufficient data for Peter to compare compensation growth.
  • Insufficient data for Peter to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Peter Lin

TITLE
Chairman and President

Hong-Chine Pai

TITLE
Chief Financial Officer

Zen Young

TITLE
Vice President of Sales - HP

Stella Chang

TITLE
Director of Consumer Products and Senior Assistant to Chief Executive Officer -Administration

Banson Lin

TITLE
Senior Assistant to Chief Executive Officer - Distributors
Board of Directors

Peter Lin

TITLE
Chairman and President
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Synmosa Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Synmosa Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4114 News

Simply Wall St News

4114 Company Info

Description

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers/DPIs, and other forms. It also offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was founded in 1980 and is based in Taipei City, Taiwan.

Details
Name: Synmosa Biopharma Corporation
4114
Exchange: GTSM
Founded: 1980
NT$5,219,542,561
219,308,511
Website: http://www.synmosa.com.tw
Address: Synmosa Biopharma Corporation
No. 396, Neihu Road,
11th Floor,
Taipei City,
114,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4114 Common Stock Taipei Exchange TW TWD 12. May 2003
Number of employees
Current staff
Staff numbers
0
Synmosa Biopharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 14:59
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/02/26
Last earnings filing: 2019/11/13
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.